\contentsline {chapter}{Introduction}{6}
\contentsline {chapter}{Lecture 1}{7}
\contentsline {section}{\numberline {1.1}Protein}{7}
\contentsline {section}{\numberline {1.2}Amino Acids}{7}
\contentsline {section}{\numberline {1.3}Amino Acid Side Chains}{8}
\contentsline {section}{\numberline {1.4}Amino Acid Subgroups}{8}
\contentsline {subsection}{\numberline {1.4.1}Non-polar}{8}
\contentsline {subsection}{\numberline {1.4.2}Uncharged Polar}{9}
\contentsline {subsection}{\numberline {1.4.3}Negatively Charged}{9}
\contentsline {subsection}{\numberline {1.4.4}Positively Charged}{9}
\contentsline {section}{\numberline {1.5}Charge of Amino Acids}{11}
\contentsline {section}{\numberline {1.6}Amino Acid Modifications}{12}
\contentsline {section}{\numberline {1.7}Proteins, Peptides, and Peptide Bonds}{13}
\contentsline {subsection}{\numberline {1.7.1}Amide (peptide) Bonds}{13}
\contentsline {chapter}{Lecture 2}{14}
\contentsline {section}{\numberline {2.1}Levels of Protein Structure}{14}
\contentsline {subsection}{\numberline {2.1.1}Primary Structure}{14}
\contentsline {subsection}{\numberline {2.1.2}Secondary Structure}{14}
\contentsline {subsection}{\numberline {2.1.3}Tertiary Structure}{14}
\contentsline {subsection}{\numberline {2.1.4}Quaternary Structure}{15}
\contentsline {section}{\numberline {2.2}Bond Rotation}{15}
\contentsline {subsection}{\numberline {2.2.1}Phi ($\phi $) Angle}{15}
\contentsline {subsection}{\numberline {2.2.2}Psi ($\Psi $) Angle}{15}
\contentsline {subsection}{\numberline {2.2.3}Omega ($\omega $) Angle}{16}
\contentsline {subsection}{\numberline {2.2.4}Chi ($\chi $) Angle}{16}
\contentsline {section}{\numberline {2.3}Ramachandron Plot}{16}
\contentsline {section}{\numberline {2.4}Secondary Structure of a Protein}{16}
\contentsline {subsection}{\numberline {2.4.1}$\alpha $-Helices}{17}
\contentsline {subsection}{\numberline {2.4.2}$\beta $-Sheets}{18}
\contentsline {subsection}{\numberline {2.4.3}Turns}{18}
\contentsline {subsection}{\numberline {2.4.4}Relationship between Ramachandron Plots and Secondary Structures}{18}
\contentsline {chapter}{Lecture 3}{20}
\contentsline {section}{\numberline {3.1}Supersecondary structure}{20}
\contentsline {section}{\numberline {3.2}Protein Domains}{20}
\contentsline {section}{\numberline {3.3}Protein Families}{21}
\contentsline {section}{\numberline {3.4}Quaternary Structure}{21}
\contentsline {section}{\numberline {3.5}Protein Folding Pathway}{21}
\contentsline {section}{\numberline {3.6}Stabilisation of Protein Folding}{21}
\contentsline {section}{\numberline {3.7}Chaperones and Chaperonin}{22}
\contentsline {chapter}{Lecture 4}{23}
\contentsline {section}{\numberline {4.1}Myoglobin}{23}
\contentsline {section}{\numberline {4.2}Haem (Heme)}{23}
\contentsline {section}{\numberline {4.3}Haemoglobin}{24}
\contentsline {section}{\numberline {4.4}O$_2$ Binding Property}{25}
\contentsline {subsection}{\numberline {4.4.1}Myoglobin}{25}
\contentsline {subsection}{\numberline {4.4.2}Haemoglobin}{25}
\contentsline {section}{\numberline {4.5}Sequential and Concerted Model of \-Allosterism}{25}
\contentsline {subsection}{\numberline {4.5.1}Sequential Model}{26}
\contentsline {subsection}{\numberline {4.5.2}Concerted Model}{26}
\contentsline {chapter}{Lecture 5}{28}
\contentsline {section}{\numberline {5.1}Allosteric Effectors of Haemoglobin}{28}
\contentsline {section}{\numberline {5.2}2,3-Bisphosphoglycerate (BPG)}{28}
\contentsline {section}{\numberline {5.3}H$^+$ and CO$_2$}{29}
\contentsline {subsection}{\numberline {5.3.1}The Bohr Effect}{29}
\contentsline {subsection}{\numberline {5.3.2}The Blood Bicarbonate Buffer System}{30}
\contentsline {chapter}{Lecture 6}{32}
\contentsline {section}{\numberline {6.1}Haemoglobin Variants}{32}
\contentsline {section}{\numberline {6.2}Normal Variants}{32}
\contentsline {subsection}{\numberline {6.2.1}Foetal Haemoglobin (HbF)}{32}
\contentsline {section}{\numberline {6.3}Abnormal Variants}{32}
\contentsline {subsection}{\numberline {6.3.1}Sickle Cell Haemoglobin (HbS)}{33}
\contentsline {subsection}{\numberline {6.3.2}Met-Haemoglobin (HbM)}{33}
\contentsline {subsection}{\numberline {6.3.3}Haemoglobin C (HbC)}{34}
\contentsline {chapter}{Lecture 7}{35}
\contentsline {section}{\numberline {7.1}Post-Translational Modification (PTM)}{35}
\contentsline {section}{\numberline {7.2}Covalent Modification of Amino Acids}{35}
\contentsline {section}{\numberline {7.3}Phoshphorylation}{35}
\contentsline {subsection}{\numberline {7.3.1}Insulin Receptor}{36}
\contentsline {subsection}{\numberline {7.3.2}Na$^+$/K$^+$ Pump}{37}
\contentsline {section}{\numberline {7.4}Gamma-carboxy Glutamic Acid (Gla)}{37}
\contentsline {section}{\numberline {7.5}Hydroxylation}{37}
\contentsline {chapter}{Lecture 8}{38}
\contentsline {section}{\numberline {8.1}Introduction to Enzymes and Enzyme Engineering}{38}
\contentsline {chapter}{Lecture 9}{39}
\contentsline {section}{\numberline {9.1}Introduction to Biotechnology}{39}
\contentsline {subsection}{\numberline {9.1.1}The `Old' Way of Obtaining Proteins}{39}
\contentsline {subsection}{\numberline {9.1.2}Recombinant Protein System}{39}
\contentsline {subsection}{\numberline {9.1.3}Eukaryotic System}{39}
\contentsline {subsection}{\numberline {9.1.4}Recombinant Antibodies}{40}
\contentsline {subsection}{\numberline {9.1.5}Pharming}{40}
\contentsline {chapter}{Lecture 10}{41}
\contentsline {section}{\numberline {10.1}Introduction to Enzymes}{41}
\contentsline {section}{\numberline {10.2}Active Site of an Enzyme}{41}
\contentsline {subsection}{\numberline {10.2.1}Geometric Specificity and Stereospecificity}{41}
\contentsline {section}{\numberline {10.3}Enzyme-Substrate Interaction}{42}
\contentsline {subsection}{\numberline {10.3.1}Lock-and-Key Model}{42}
\contentsline {subsection}{\numberline {10.3.2}Induced-fit Model}{42}
\contentsline {section}{\numberline {10.4}Enzymes, Activation Energy, and \\Catalytic Mechanisms}{42}
\contentsline {subsection}{\numberline {10.4.1}Acid-base Catalysis}{43}
\contentsline {subsection}{\numberline {10.4.2}Covalent Catalysis}{43}
\contentsline {subsection}{\numberline {10.4.3}Metal Ion Catalysis}{43}
\contentsline {section}{\numberline {10.5}Co-factors and Co-enzymes/Co-substrates}{44}
\contentsline {section}{\numberline {10.6}Enzyme Nomenclature}{44}
\contentsline {chapter}{Lecture 11}{45}
\contentsline {section}{\numberline {11.1}Enzyme Kinetics}{45}
\contentsline {section}{\numberline {11.2}Measuring Enzyme Catalysis}{45}
\contentsline {section}{\numberline {11.3}Effect of Enzyme Concentration on the Rate of Reaction}{45}
\contentsline {section}{\numberline {11.4}Effect of Substrate Concentration on the Rate of Reaction}{46}
\contentsline {subsection}{\numberline {11.4.1}V$_{max}$ and K$_M$}{46}
\contentsline {chapter}{Lecture 12}{47}
\contentsline {section}{\numberline {12.1}The Michaelis-Menten Equation}{47}
\contentsline {section}{\numberline {12.2}Lineweaver-Burk Plot}{47}
\contentsline {section}{\numberline {12.3}Significance of K$_M$}{48}
\contentsline {section}{\numberline {12.4}Physiological Significance of K$_M$}{48}
\contentsline {section}{\numberline {12.5}V$_{max}$ and k$_{cat}$}{49}
\contentsline {section}{\numberline {12.6}k$_{cat}$, K$_M$ and Catalytic Efiiciency}{49}
\contentsline {chapter}{Lecture 13}{50}
\contentsline {section}{\numberline {13.1}Enzyme Inhibitor}{50}
\contentsline {section}{\numberline {13.2}Irreversible Inhibitors}{50}
\contentsline {section}{\numberline {13.3}Reversible Inhibitors}{50}
\contentsline {subsection}{\numberline {13.3.1}Competitive Reversible Inhibitor}{51}
\contentsline {subsection}{\numberline {13.3.2}Non-competitive Reversible Inhibitor}{51}
\contentsline {section}{\numberline {13.4}Methods of Enzyme Regulation}{51}
\contentsline {subsection}{\numberline {13.4.1}Allosteric Enzyme Regulation}{51}
\contentsline {subsection}{\numberline {13.4.2}Covalent Modification of Enzymes}{52}
\contentsline {subsection}{\numberline {13.4.3}Activation of Enzymes by Cleavage}{52}
\contentsline {section}{\numberline {13.5}Isoenzymes/Isozymes}{52}
\contentsline {chapter}{Lecture 14}{53}
\contentsline {section}{\numberline {14.1}Pharmacology and Toxicology}{53}
\contentsline {section}{\numberline {14.2}Drugs}{53}
\contentsline {subsection}{\numberline {14.2.1}Sources of Drugs}{53}
\contentsline {subsection}{\numberline {14.2.2}Targets of Drugs}{53}
\contentsline {section}{\numberline {14.3}Agonists and Antagonists}{54}
\contentsline {section}{\numberline {14.4}Receptors}{54}
\contentsline {subsection}{\numberline {14.4.1}Drug Receptor}{54}
\contentsline {subsection}{\numberline {14.4.2}Physiological Receptor}{54}
\contentsline {section}{\numberline {14.5}Ligand-Gated Ion Channels}{54}
\contentsline {section}{\numberline {14.6}Voltage-Gated Ion Channels}{55}
\contentsline {chapter}{Lecture 15}{56}
\contentsline {section}{\numberline {15.1}Nuclear Receptor}{56}
\contentsline {section}{\numberline {15.2}Mechanism of Nuclear Receptor Signalling}{56}
\contentsline {subsection}{\numberline {15.2.1}Regulation of Nuclear Receptor}{56}
\contentsline {section}{\numberline {15.3}Structure of Nuclear Receptor}{57}
\contentsline {section}{\numberline {15.4}What Genes are Activated by Nuclear Receptor}{57}
\contentsline {section}{\numberline {15.5}Nuclear Receptor and Cancer}{57}
\contentsline {subsection}{\numberline {15.5.1}Breast Cancer}{57}
\contentsline {subsection}{\numberline {15.5.2}Androgen Receptor and Prostate Cancer}{58}
\contentsline {section}{\numberline {15.6}Effect of Hormones on Living Organisms}{58}
\contentsline {chapter}{Lecture 16}{59}
\contentsline {section}{\numberline {16.1}G-protein Coupled Receptors (GPCR)}{59}
\contentsline {section}{\numberline {16.2}Mechanism of GPCRs}{59}
\contentsline {section}{\numberline {16.3}Dopamine Receptor}{59}
\contentsline {subsection}{\numberline {16.3.1}Parkinson's Disease}{60}
\contentsline {subsection}{\numberline {16.3.2}Psychosis}{60}
